Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693809 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL7431595 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL13428611 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL13428637 | 0.88 | MAPT (0.35) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL13428645 | 0.88 | MAPT (0.35) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL3155023 | 0.88 | MAPT (0.35) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL15158556 | 0.88 | HTR2A (0.37) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL15158554 | 0.88 | HTR2A (0.37) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL4247917 | 0.88 | HTR2A (0.37) | CYP3A4MAPTMAOAALDH1A1CYP2D6 | |
| SCHEMBL7543257 | 0.86 | HTR2C (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | claimed |
| EP-2566850-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE HYDROBROMIDE SALT | RICHTER GEDEON NYRT (HU) | 2018-04-11 | — | — | EP | claimed |
| EP-2566850-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE SALTS | Richter Gedeon Nyrt. (HU) | 2013-03-13 | — | — | EP | claimed |
| WO-2011138625-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE SALTS | RICHTER GEDEON NYRT. (HU) | 2011-11-10 | — | — | WO | claimed |
| CN-114324714-B | Method for detecting (1S) -4, 5-dimethoxy-1- [ (methylamino) methyl ] benzocyclobutane hydrochloride | 海南鑫开源医药科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-114324714-A | Method for detecting (1S) -4, 5-dimethoxy-1- [ (methylamino) methyl ] benzocyclobutane hydrochloride | 海南鑫开源医药科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | disclosed |
| EP-2566850-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE HYDROBROMIDE SALT | RICHTER GEDEON NYRT (HU) | 2018-04-11 | — | — | EP | disclosed |
| EP-2566850-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF IVABRADINE HYDROBROMIDE SALT | RICHTER GEDEON NYRT (HU) | 2018-04-11 | — | — | EP | disclosed |
| EP-2803659-B1 | Method for synthesising 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile and use for synthesising ivabradine and the added salts thereof with a pharmaceutically acceptable acid | SERVIER LAB (FR) | 2017-01-04 | — | — | EP | disclosed |
| EP-2803659-B1 | Method for synthesising 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile and use for synthesising ivabradine and the added salts thereof with a pharmaceutically acceptable acid | SERVIER LAB (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-20050261376-A1 | PROCESS FOR THE SYNTHESIS OF (IS)-4,5-DIMETHOXY-1-(METHYLAMINOMETHYL)-BENZOCYCLOBUTANE AND ADDITION SALTS THEREOF, AND TO THE APPLICATION THEREOF IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1598333-A1 | Process for the preparation of (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, acid addition salts thereof and its use for the synthesis of ivabradine and for its pharmaceutically acceptable acid addition salts | Les Laboratoires Servier (FR) | 2005-11-23 | — | — | EP | disclosed |
| EP-0940386-B1 | Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-05-22 | — | — | EP | disclosed |
| US-6107345-A | ANTIDEPRESSANT; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 2000-08-22 | — | — | US | disclosed |
| EP-0940386-A1 | Benzocyclobutan compounds, their process for preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-09-08 | — | — | EP | disclosed |
| US-5296482-A | (Benzocycloalkyl) alkylamines | ADIR ET COMPAGNIE (FR) | 1994-03-22 | — | — | US | disclosed |
| US-4567181-A | Bicyclo (4.2.0) 1,3,5-octatriene compounds and use as α-adrenergics | ADIR, S.A.R.L. (FR) | 1986-01-28 | — | — | US | disclosed |
| EP-0043194-A2 | Bicyclo-octatriene derivatives, pharmaceutical compositions containing them and processes and intermediates for their production | FISONS plc (GB) | 1982-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261376-A1 | PROCESS FOR THE SYNTHESIS OF (IS)-4,5-DIMETHOXY-1-(METHYLAMINOMETHYL)-BENZOCYCLOBUTANE AND ADDITION SALTS THEREOF, AND TO THE APPLICATION THEREOF IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4B1, CYP4F2, CYP2S1 | CYP3A4 12/4885MAPT 4805/4885MAOA 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.